| abstract |
The present invention relates to a pharmaceutical composition that inhibits the function of B cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and reduces the level thereof, and for treating Bmi-1 mediated cancer. Methods of their use to inhibit Bmi-1 function and reduce Bmi-1 levels. A pharmaceutical composition comprising a compound, wherein the compound is 5-fluoro-2- (6-fluoro-2-methyl-1H-benzimidazol-1-yl) -N- [4- (tri Fluoromethyl) phenyl] pyrimidine-4,6-diamine, or a pharmaceutically acceptable salt thereof. [Selection diagram] None |